{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:28Z","timestamp":1790791528915,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:00:00Z","timestamp":1549324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00016","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T07:57:57Z","timestamp":1549353477000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Heparins Sourced From Bovine and Porcine Mucosa Gain Exclusive Monographs in the Brazilian Pharmacopeia"],"prefix":"10.3389","volume":"6","author":[{"given":"Eduardo","family":"Vilanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno C.","family":"Vairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan-Nicollas M. C. G.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca F.","family":"Glauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina V.","family":"Capill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo R. C.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M. F.","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo A. S.","family":"Mour\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/JBM.S149202","article-title":"Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk\/benefit assessment","volume":"9","author":"Al","year":"2018","journal-title":"J Blood Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"E1025","DOI":"10.3390\/molecules22061025","article-title":"From farm to pharma: an overview of industrial heparin manufacturing methods","volume":"22","author":"van","year":"2017","journal-title":"Molecules"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-642-23056-1_1","article-title":"History of heparin","volume":"207","author":"Barrowcliffe","year":"2012","journal-title":"Handb Exp Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1208\/s12248-017-0047-y","article-title":"A heparin purification process removes spiked transmissible spongiform encephalopathy agent","volume":"19","author":"Bett","year":"2017","journal-title":"AAPS J."},{"key":"B5","first-page":"28","article-title":"Diversifying the global heparin supply chain. Reintroduction of bovine heparin in the United States?","volume":"39","author":"Keire","year":"2015","journal-title":"Pharm Technol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1160\/TH09-11-0761","article-title":"Heparins from porcine and bovine intestinal mucosa: are they similar drugs?","volume":"103","author":"Aquino","year":"2010","journal-title":"Thromb Haemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.drudis.2014.07.004","article-title":"Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs","volume":"19","author":"Santos","year":"2014","journal-title":"Drug Discov Today"},{"key":"B8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1160\/th11-07-0518","article-title":"Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects","volume":"107","author":"Tovar","year":"2012","journal-title":"Thromb Haemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"35619","DOI":"10.1038\/srep35619","article-title":"Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs","volume":"6","author":"Tovar","year":"2016","journal-title":"Sci Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/jth.14221","article-title":"Chemical and pharmacological aspects of the neutralization of heparins from different animal sources by protamine","volume":"16","author":"Glauser","year":"2018","journal-title":"J Thromb Haemost."},{"key":"B11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1590\/S0102-76382008000200004","article-title":"Heparin quality control in the Brazilian market: implications in the cardiovascular surgery","volume":"23","author":"Melo","year":"2008","journal-title":"Ver Bras Cir Cardiovasc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-642-23056-1_4","article-title":"Standardisation of unfractionated and low-molecular-weight heparin","volume":"207","author":"Gray","year":"2012","journal-title":"Handb Exp Pharmacol."},{"key":"B13","article-title":"S. Pharmacopoeia-National Formulary","volume-title":"Heparin Sodium Monograph: USP41-NF36","year":"2018"},{"key":"B14","volume-title":"Heparin Sodium Monograph: EP","author":"European","year":"2018"},{"key":"B15","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.3390\/ph10030059","article-title":"Precipitation and neutralization of heparin from different sources by protamine sulfate","volume":"10","author":"Hogwood","year":"2017","journal-title":"Pharmaceuticals"},{"key":"B16","first-page":"147","article-title":"Stability of ester sulfates in heparin to solvolysis and dilute acid treatment","volume":"86","author":"Kosakai","year":"1979","journal-title":"Biochemistry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1055\/s-0038-1649910","article-title":"Differentiation of beef and pig mucosal heparins by NMR spectroscopy","volume":"74","author":"Casu","year":"1995","journal-title":"Thromb Haemost."},{"key":"B18","first-page":"472","article-title":"Characterization of sulfation patterns of beef and pig mucosal heparins by nuclear magnetic resonance spectroscopy","volume":"46","author":"Casu","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"B19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-2001-17958","article-title":"Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations","volume":"27","author":"Guerrini","year":"2001","journal-title":"Semin Thromb Hemost."},{"key":"B20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0076-6879(93)22033-C","article-title":"Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin","volume":"222","author":"Olson","year":"1993","journal-title":"Methods Enzymol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/DDDT.S162817","article-title":"Bioequivalence of a biosimilar enoxaparin sodium to Clexane\u00ae after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers","volume":"12","author":"Mart\u00ednez","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/pds.1991","article-title":"Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008","volume":"19","author":"McMahon","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0193482","DOI":"10.1371\/journal.pone.0193482","article-title":"The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system","volume":"13","author":"Hogwood","year":"2018","journal-title":"PLoS ONE"},{"key":"B24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nbt1407","article-title":"Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events","volume":"26","author":"Guerrini","year":"2008","journal-title":"Nat Biotechnol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/S0102-76382009000200002","article-title":"The troubled heparin issue in the Brazilian market and the search for solutions","volume":"24","author":"Gomes","year":"2009","journal-title":"Rev Bras Cir Cardiovasc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0104-4230(11)70067-7","article-title":"Heparin pharmacovigilance in Brazil","volume":"57","author":"Junqueira","year":"2011","journal-title":"Rev Assoc Med Bras."},{"key":"B27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-642-23056-1_11","article-title":"Neutralization of heparin activity","volume":"207","author":"Pai","year":"2012","journal-title":"Handb Exp Pharmacol."},{"key":"B28","volume-title":"Heparin Sodium Monograph: Brazilian Pharmacopeia","author":"Brazilian","year":"2009"},{"key":"B29","volume-title":"Bovine Heparin Sodium Monograph: Brazilian Pharmacopeia","author":"Brazilian","year":"2017"},{"key":"B30","volume-title":"Porcine Heparin Sodium Monograph: Brazilian Pharmacopeia","author":"Brazilian","year":"2016"},{"key":"B31","volume-title":"Heparin Sodium Injectable Solution Monograph: Brazilian Pharmacopeia","author":"Brazilian","year":"2016"},{"key":"B32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0049-3848(79)90035-5","article-title":"Anticoagulant activity of beef and hog mucosal heparins","volume":"14","author":"Aiach","year":"1979","journal-title":"Thromb Res."},{"key":"B33","first-page":"406","article-title":"Pharmacological activities of heparins obtained from different tissues: enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography","volume":"220","author":"Bianchini","year":"1982","journal-title":"J Pharmacol Exp Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0049-3848(77)90029-9","article-title":"Anticoagulant activity of heparin: assay of bovine,human and porcine preparations by amidolytic and clotting methods","volume":"11","author":"Teien","year":"1977","journal-title":"Thromb Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1002\/jps.21729","article-title":"Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE","volume":"98","author":"Zhang","year":"2009","journal-title":"J Pharm Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jpba.2015.10.001","article-title":"Structural peculiarity and antithrombin binding region profile of mucosal bovine and porcine heparins","volume":"118","author":"Naggi","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"B37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.carbpol.2016.09.061","article-title":"Biological and structural analyses of bovine heparin fractions of intermediate and high molecular weight","volume":"157","author":"Nogueira","year":"2017","journal-title":"Carbohydr Polym."},{"key":"B38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/MBC.0000000000000161","article-title":"Addition of prothrombin to plasma can result in a paradoxical increase in activated partial thromboplastin time","volume":"25","author":"Hansson","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1021\/acs.jmedchem.7b01269","article-title":"Enzymatic generation of highly anticoagulant bovine intestinal heparin","volume":"60","author":"Fu","year":"2017","journal-title":"J Med Chem."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14372","article-title":"Imminent risk of a global shortage of heparin caused by the African Swine Flu afflicting the Chinese pig herd","author":"Vilanova","year":"2018","journal-title":"J. Thromb. Haemost"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/17474086.2016.1243052","article-title":"Update on Brazilian biosimilar enoxaparins","volume":"9","author":"Vilanova","year":"2016","journal-title":"Expert Rev Hematol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T07:58:01Z","timestamp":1549353481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,5]]},"references-count":41,"alternative-id":["10.3389\/fmed.2019.00016"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00016","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,5]]},"article-number":"16"}}